U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182227) titled 'PS-002 for the Treatment of IgA Nephropathy in Adults' on Sept. 11.
Brief Summary: The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary IgA nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment.
Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Immu...